High Dose CHOP in Lymphoma

Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00192764

Enrollment

Registered

2005-09-19

Start date

1996-12-31

Completion date

2010-09-30

Last updated

2010-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin's Lymphoma

Keywords

large cell lymphoma, CHOP, cyclophosphamide, high-dose

Brief summary

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Interventions

DRUGhigh-dose cyclophosphamide

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* large-cell non-Hodgkin's lymphoma * IPI low-intermediate, high-intermediate and high or bulky mediastinum * age 18-65

Exclusion criteria

* previous treatment for lymphoma * serious concurrent systemic disease

Design outcomes

Primary

Measure	Time frame
Failure-free survival	—

Secondary

Measure	Time frame
overall survival	—
response rate	—
toxicity	—

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026